PITTSBURGH, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the fourth quarter and year ending December 31, 2023.
“2023 was an inflection point for Krystal with the approval and launch of VYJUVEK, the first-ever FDA approved therapy for dystrophic epidermolysis bullosa and only medicine that delivers the corrective power of gene therapy in an easy-to-apply, redosable, topical gel formulation that can be administered at home,” said Krish S. Krishnan, Chairman and CEO of Krystal Biotech. “Our U.S. commercial launch trajectory is tracking closely to that of the best recent rare disease launches with $50.7 million in net product revenue only six months since approval, supported by high patient and physician demand, broad access, and high compliance. We look forward to expanding VYJUVEK access in the U.S. and globally in the years to come, while advancing our clinical pipeline and reinforcing our leadership in redosable gene therapy.”
VYJUVEK for the treatment of Dystrophic Epidermolysis Bullosa (DEB)
Respiratory
KB407 for the treatment of cystic fibrosis (CF)
KB408 for the treatment of alpha-1 antitrypsin deficiency (AATD)
Ophthalmology
Oncology
KB707 for the treatment of solid tumors
Aesthetics
KB301 for the treatment of Aesthetic Indications
Financial results for the quarter ended December 31, 2023:
Financial results for the year ended December 31, 2023
Financial Guidance
($ in millions) | FY 2024 Guidance | |
Non-GAAP Research and Development (“R&D”) and Selling, General and Administrative (“SG&A”) expense(1) | $150.0 - $175.0 | |
(1) Refer to Non-GAAP Financial Measures section below for additional information. Non-GAAP combined R&D and SG&A expense guidance does not include stock-based compensation as we are currently unable to confidently estimate Full Year 2024 stock-based compensation expense. As such, we have not provided a reconciliation from forecasted non-GAAP to forecasted GAAP combined R&D and SG&A Expense in the above. This could materially affect the calculation of forward-looking GAAP combined R&D and SG&A Expense as it is inherently uncertain.
Conference Call
The Company will host an investor webcast on Monday, February 26, 2024 at 8:30 am ET.
Investors and the general public can access the live webcast at https://www.webcaster4.com/Webcast/Page/3018/49928.
For those unable to listen to the live conference call, a replay will be available for 30-days on the Investors section of the Company’s website at www.krystalbio.com.
About VYJUVEK
VYJUVEK is a non-invasive, topical, redosable gene therapy designed to deliver two copies of the COL7A1 gene when applied directly to DEB wounds. VYJUVEK was designed to treat DEB at the molecular level by providing the patient’s skin cells the template to make normal COL7 protein, thereby addressing the fundamental disease-causing mechanism.
Indication
VYJUVEK is a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy indicated for the treatment of wounds in patients six months of age and older with dystrophic epidermolysis bullosa with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.
IMPORTANT SAFETY INFORMATION
Adverse Reactions
The most common adverse drug reactions (incidence >5%) were itching, chills, redness, rash, cough, and runny nose. These are not all the possible side effects with VYJUVEK. Call your healthcare provider for medical advice about side effects.
To report SUSPECTED ADVERSE REACTIONS, contact Krystal Biotech, Inc. at 1-844-557-9782 or FDA at 1-800-FDA-1088 or https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program.
Contraindications
None.
Warnings and Precautions
VYJUVEK gel must be applied by a healthcare provider.
After treatment, patients and caregivers should be careful not to touch treated wounds and dressings for 24 hours.
Wash hands and wear protective gloves when changing wound dressings. Disinfect bandages from the first dressing change with a virucidal agent, and dispose of the disinfected bandages in a separate sealed plastic bag in household waste. Dispose of the subsequent used dressings in a sealed plastic bag in household waste.
Patients should avoid touching or scratching wound sites or wound dressings.
In the event of an accidental exposure flush with clean water for at least 15 minutes.
For more information, see full U.S. Prescribing Information.
About Orphan Drug Designation
Orphan Drug Designation is granted by the U.S. FDA to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the U.S. Orphan drug status provides benefits to drug developers, including assistance in the drug development process, tax credits for clinical costs, exemptions from certain U.S. FDA fees and seven years of post-approval marketing exclusivity.
The orphan drug designation system in Japan aims to support the development of drugs for diseases that affect fewer than 50,000 patients in Japan, for which significant unmet medical need exists. An investigational therapy is eligible to qualify for ODD if there is no approved alternative treatment option or if there is high efficacy or safety compared to existing treatment options expected. Specific measures to support the development of orphan drugs include subsidies for research and development expenditures, prioritized consultation regarding clinical development, reduced consultation fees, tax incentives, priority review of applications, reduced application fees, and extended registration validity period.
About Fast Track Designation
Fast Track Designation is designed to facilitate the development and expedite the review of drugs to treat serious conditions and treat a serious or unmet medical need, enabling drugs to reach patients sooner. Clinical programs with Fast Track Designation may benefit from early and frequent communication with the FDA throughout the regulatory review process, and such clinical programs may be eligible to apply for Accelerated Approval and Priority Review if relevant criteria are met.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
About Jeune Aesthetics, Inc.
Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal Biotech, Inc., is a biotechnology company leveraging a clinically validated gene-delivery platform to develop products to fundamentally address – and reverse – the biology of aging and/or damaged skin. For more information, please visit http://www.jeuneinc.com.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Krystal Biotech, Inc. or Jeune Aesthetics, Inc., including statements about the Company’s commercial launch of VYJUVEK in the United States and expanding VYJUVEK access in the U.S. and globally; the Company’s anticipation of potential B-VEC approval for the treatment of DEB in patients from birth in the EU in 2H 2024; the Company’s intention to file a Japanese New Drug Application for B-VEC for the treatment of DEB patients in 2H 2024 enabling a potential authorization in 2025; the Company’s plans to announce interim data from its Phase 1 study of KB408 in 2H 2024; the Company’s plans to initiate a study in 2H 2024 of B-VEC eyedrops for the treatment of lesions in the eye of DEB patients; the Company expectations regarding dosing of the first patient with inhaled KB707 for the treatment of patients with locally advanced or metastatic solid tumors of the lung in its Phase 1 clinical study in 1H 2024; Jeune Aesthetics’ plans to announce results in 1H 2024 of Cohort 4 of its Phase 1 clinical study to evaluate KB301 for the improvement of dynamic wrinkles of the décolleté and Cohort 3 to evaluate KB301 for the improvement of lateral canthal lines at rest; and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; the availability or commercial potential of VYJUVEK or product candidates; the sufficiency of cash resources and need for additional financing; and such other important factors as are set forth under the caption “Risk Factors” in the Company’s annual and quarterly reports on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release. This press release also contains estimates and other statistical data made by independent parties and by the Company that involves a number of assumptions and limitations. Neither the Company nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this press release.
Non-GAAP Financial Measures
This press release includes forward looking combined R&D and SG&A expense guidance that is not required by, or presented in accordance with, U.S. GAAP and should not be considered as an alternative to R&D and SG&A expense or any other performance measure derived in accordance with GAAP. The Company defines non-GAAP combined R&D and SG&A expense as GAAP combined R&D and SG&A expense excluding stock-based compensation. The Company cautions investors that amounts presented in accordance with its definition of non-GAAP combined R&D and SG&A expense may not be comparable to similar measures disclosed by competitors because not all companies calculate this non-GAAP financial measure in the same manner. The Company presents this non-GAAP financial measure because it considers this measure to be an important supplemental measure and believes it is frequently used by securities analysts, investors, and other interested parties in the evaluation of companies in the Company’s industry. Management believes that investors’ understanding of the Company’s performance is enhanced by including this forward-looking non-GAAP financial measure as a reasonable basis for comparing the Company’s ongoing results of operations. Management uses this non-GAAP financial measure for planning purposes, including the preparation of the Company’s internal annual operating budget and financial projections; to evaluate the performance and effectiveness of the Company’s operational strategies; and to evaluate the Company’s capacity to expand its business. This non-GAAP financial measure has limitations as an analytical tool, and should not be considered in isolation, or as an alternative to, or a substitute for R&D and SG&A expense or other financial statement data presented in accordance with GAAP in the Company’s consolidated financial statements. The Company has not provided a quantitative reconciliation of forecasted non-GAAP combined R&D and SG&A expense to forecasted GAAP combined R&D and SG&A expense because the Company is unable, without making unreasonable efforts, to calculate the reconciling item, stock-based compensation expenses, with confidence. This item, which could materially affect the computation of forward-looking GAAP combined R&D and SG&A expense, is inherently uncertain.
CONTACT
Investors and Media:
Meg Dodge
Krystal Biotech
This email address is being protected from spambots. You need JavaScript enabled to view it.
Condensed Consolidated Balance Sheet:
(In thousands) | December 31, 2023 | December 31, 2022 | |||||
Balance sheet data: | |||||||
Cash and cash equivalents | $ | 358,328 | $ | 161,900 | |||
Short-term investments | 173,850 | 217,271 | |||||
Long-term investments | 61,954 | 4,621 | |||||
Total assets | 818,355 | 558,450 | |||||
Total liabilities | 39,714 | 36,219 | |||||
Total stockholders’ equity | $ | 778,641 | $ | 522,231 | |||
Consolidated Statement of Operations:
Three Months Ended December 31, | ||||||||||||
(in thousands, except shares and per share data) | 2023 | 2022 | Change | |||||||||
Revenue | ||||||||||||
Product revenue, net | $ | 42,143 | $ | — | $ | 42,143 | ||||||
Expenses | ||||||||||||
Cost of goods sold | 2,871 | — | 2,871 | |||||||||
Research and development | 11,370 | 10,741 | 629 | |||||||||
Selling, general and administrative | 24,764 | 24,030 | 734 | |||||||||
Total operating expenses | 39,005 | 34,771 | 4,234 | |||||||||
Income (loss) from operations | 3,138 | (34,771 | ) | 37,909 | ||||||||
Other Income | ||||||||||||
Interest and other income, net | 7,519 | 2,719 | 4,800 | |||||||||
Income (loss) before income taxes | 10,657 | (32,052 | ) | 42,709 | ||||||||
Income tax expense | (1,965 | ) | — | (1,965 | ) | |||||||
Net income (loss) | $ | 8,692 | $ | (32,052 | ) | $ | 40,744 | |||||
Net income (loss) per common share | ||||||||||||
Basic | 0.31 | (1.25 | ) | |||||||||
Diluted | 0.30 | (1.25 | ) | |||||||||
Weighted-average common shares outstanding: | ||||||||||||
Basic | 28,168,776 | 25,680,520 | ||||||||||
Diluted | 28,817,823 | 25,680,520 |
Years Ended December 31, | |||||||||||
(in thousands, except shares and per share data) | 2023 | 2022 | Change | ||||||||
Revenue | |||||||||||
Product revenue, net | $ | 50,699 | $ | — | $ | 50,699 | |||||
Expenses | |||||||||||
Cost of goods sold | 3,094 | — | 3,094 | ||||||||
Research and development | 46,431 | 42,461 | 3,970 | ||||||||
Selling, general and administrative | 98,401 | 77,735 | 20,666 | ||||||||
Litigation settlement | 12,500 | 25,000 | (12,500 | ) | |||||||
Total operating expenses | 160,426 | 145,196 | 15,230 | ||||||||
Income (loss) from operations | (109,727 | ) | (145,196 | ) | 35,469 | ||||||
Other Income | |||||||||||
Gain from sale of Priority Review Voucher | 100,000 | — | 100,000 | ||||||||
Interest and other income, net | 22,624 | 5,221 | 17,403 | ||||||||
Income (loss) before income taxes | 12,897 | (139,975 | ) | 152,872 | |||||||
Income tax expense | (1,965 | ) | — | (1,965 | ) | ||||||
Net income (loss) | $ | 10,932 | $ | (139,975 | ) | $ | 150,907 | ||||
Net income (loss) per common share: | |||||||||||
Basic | $ | 0.40 | $ | (5.49 | ) | ||||||
Diluted | $ | 0.39 | $ | (5.49 | ) | ||||||
Weighted-average common shares outstanding: | |||||||||||
Basic | 27,154,190 | 25,491,721 | |||||||||
Diluted | 27,751,809 | 25,491,721 |
Last Trade: | US$184.19 |
Daily Change: | -1.87 -1.01 |
Daily Volume: | 86,190 |
Market Cap: | US$5.290B |
September 06, 2024 August 05, 2024 May 15, 2024 |
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB